How tumor-derived GABA disables tumor TLSs and drives anti-PD-1 resistance in cancer
MaaT Pharma: Advancing a pipeline of novel microbiome therapies across oncology
Enhanced anti-tumor response to anti-angiogenic / hypoxia-regulating therapies in combination with immune checkpoint blockade in a murine model of renal carcinoma
Background Antiangiogenic and other targeted therapies have shown efficacy in both preclinical and clinical settings. However, tumors can acquire resistance, allowing them to survive and grow under hypoxic conditions. In this context, combining angiogenesis- and/or hypoxia-targeted strategies with immune checkpoint inhibitors, such as anti-PD1 or anti-PDL1 antibodies, is of particular interest. These therapeutic combinations may […]
Can a single gut bacterium rescue failing immunotherapy? F. prausnitzii strain EXL01 restores checkpoint-inhibitor response
Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
Does acetaminophen blunt cancer immunotherapy? Plasma evidence links paracetamol to worse checkpoint-inhibitor outcomes
Low plasma Arginine level is associated with resistance to immune checkpoint inhibitors in patients with advanced cancer
Background In the era of immuno-oncology, identifying primary resistance mechanisms to immune checkpoint inhibitors remains crucial. A better understanding of these mechanisms may help to identify novel pathways that can be targeted to improve response rates, as well as biomarkers that could support the selection of patients more likely to benefit from cancer immunotherapies. Among […]
Development and characterization of a novel anti-PD1 resistant sarcoma mouse model
Soft tissue sarcoma (STS) is known to be resistant to cancer immunotherapy, including prototypical immune checkpoint inhibitors such as anti-PD1 antibodies. It is therefore crucial to develop innovative strategies aimed at improving current clinical benefit. To support this objective, well-characterized sarcoma preclinical models that mimic resistance to immunotherapy are needed. Starting from the anti-PD(L)1-sensitive MCA205 […]
How CD95/Fas helps triple-negative breast cancer escape NK-cell control in preclinical models
Comprehensive assessment of anti-tumor PDL1 blockade effect in a sarcoma mouse model
Background Development of novel immunotherapeutics in oncology is of major interest. Their preclinical evaluation relies on two key elements: the relevance of the animal model used and the implementation of a comprehensive strategy to deeply characterize the mechanisms underlying drug resistance or sensitivity. Methods Using a syngeneic sarcoma mouse model treated with anti-PD-L1, we investigated […]